KR20200037796A - 암 치료를 위한 염색체 불안정성 및 다운스트림 사이토졸 dna 시그널링의 표적화 - Google Patents

암 치료를 위한 염색체 불안정성 및 다운스트림 사이토졸 dna 시그널링의 표적화 Download PDF

Info

Publication number
KR20200037796A
KR20200037796A KR1020207003861A KR20207003861A KR20200037796A KR 20200037796 A KR20200037796 A KR 20200037796A KR 1020207003861 A KR1020207003861 A KR 1020207003861A KR 20207003861 A KR20207003861 A KR 20207003861A KR 20200037796 A KR20200037796 A KR 20200037796A
Authority
KR
South Korea
Prior art keywords
cells
cell
cgamp
sample
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207003861A
Other languages
English (en)
Korean (ko)
Inventor
루이스 씨. 캔틀리
브라이언 엔고
사무엘 에프. 바쿰
Original Assignee
코넬 유니버시티
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코넬 유니버시티, 메모리얼 슬로안 케터링 캔서 센터 filed Critical 코넬 유니버시티
Publication of KR20200037796A publication Critical patent/KR20200037796A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
KR1020207003861A 2017-07-10 2018-07-10 암 치료를 위한 염색체 불안정성 및 다운스트림 사이토졸 dna 시그널링의 표적화 Withdrawn KR20200037796A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
US62/530,661 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
KR20200037796A true KR20200037796A (ko) 2020-04-09

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003861A Withdrawn KR20200037796A (ko) 2017-07-10 2018-07-10 암 치료를 위한 염색체 불안정성 및 다운스트림 사이토졸 dna 시그널링의 표적화

Country Status (12)

Country Link
US (2) US11821042B2 (enExample)
EP (1) EP3652349A1 (enExample)
JP (1) JP7197556B2 (enExample)
KR (1) KR20200037796A (enExample)
CN (1) CN111295454A (enExample)
AU (1) AU2018300007A1 (enExample)
BR (1) BR112020000477A2 (enExample)
CA (1) CA3069515A1 (enExample)
IL (1) IL271849A (enExample)
MX (1) MX2020000406A (enExample)
SG (1) SG11202000132WA (enExample)
WO (1) WO2019014246A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017318610B2 (en) * 2016-09-02 2021-12-09 The Board Of Trustees Of The University Of Illinois KIF13B-derived peptide and method of inhibiting Angiogenesis
BR112020000477A2 (pt) 2017-07-10 2020-07-21 Cornell University ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
EP3987291A1 (en) * 2019-06-21 2022-04-27 IFM Due, Inc. Methods of treating cancer
EP4110343B1 (en) * 2020-02-19 2026-04-08 Instituto De Biologia Molecular E Celular - IBMC 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence
EP4160181A4 (en) * 2020-05-28 2024-08-07 Wang, Daoxiang METHOD FOR PREPARING MULTIPLE STAINING SECTIONS FOR A CYTOPATHOLOGY SAMPLE
US20230324392A1 (en) * 2020-09-02 2023-10-12 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers
EP4326726A4 (en) * 2021-04-23 2025-03-26 Baruch S. Blumberg Institute METHODS, KITS AND COMPOSITIONS FOR REDUCING CHROMOSOMALIC INSTABILITY IN CANCER CELLS
CN113341154B (zh) * 2021-05-14 2024-11-05 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
CN115354078B (zh) * 2022-09-02 2023-07-07 中山大学附属第一医院 骨肉瘤检测标记物及其应用
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU1508899A (en) 1997-12-02 1999-06-16 Chong Kun Dang Corporation Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
PT2934598T (pt) 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
WO2015036643A2 (es) 2013-09-13 2015-03-19 Sierra Jiménez Angels Marcador para predecir metástasis del cancer de mama
BR112016020897A2 (en) * 2014-03-11 2018-01-23 The Council Of The Queensland Institute Of Medical Research Determination of cancer aggressiveness, prognosis, and responsiveness to treatment
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis
US10329258B2 (en) 2015-04-30 2019-06-25 University Of Washington CGAS in systemic lupus erythematosus (SLE)
BR112020000477A2 (pt) 2017-07-10 2020-07-21 Cornell University ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer

Also Published As

Publication number Publication date
US11821042B2 (en) 2023-11-21
CA3069515A1 (en) 2019-01-17
US20240110246A1 (en) 2024-04-04
CN111295454A (zh) 2020-06-16
JP7197556B2 (ja) 2022-12-27
SG11202000132WA (en) 2020-02-27
WO2019014246A1 (en) 2019-01-17
AU2018300007A1 (en) 2020-02-27
JP2020526206A (ja) 2020-08-31
BR112020000477A2 (pt) 2020-07-21
MX2020000406A (es) 2020-10-01
US20210130903A1 (en) 2021-05-06
IL271849A (en) 2020-02-27
EP3652349A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
US20240110246A1 (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
US11873486B2 (en) Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
WO2021247540A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
KR20210040948A (ko) 단핵구 및 대식세포의 염증성 표현형을 조절하기 위한 조성물 및 방법, 그리고 이의 면역요법 용도
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
KR20100095564A (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
US12005073B2 (en) Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
US20230105008A1 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
CN116583537A (zh) 与对过继细胞疗法的应答相关的t细胞表型
US20240280561A1 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
CA3212132A1 (en) Methods of treating red blood cell disorders
US20260117178A1 (en) Means to treat autoimmunity by refining regulatory t cells
CA3023980C (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210709

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20231205

WITB Written withdrawal of application